Oncology Letters : Impact Factor & More
eISSN: 1792-1082pISSN: 1792-1074
Share this on:
Key Metrics
CiteScore 
5.8
Impact Factor
< 5
SJR
Q3Oncology
SNIP
0.73
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Oncology Letters
Oncology Letters Journal Specifications
| Overview | |
| Publisher | SPANDIDOS PUBL LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2010 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Oncology Letters ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Oncology Letters
Expression of Concern] In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism.
- 1 Jul 2026
- Oncology letters
Expression of Concern] Long non-coding RNA BX357664 inhibits cell proliferation and metastasis in human lung cancer.
- 1 Jun 2026
- Oncology letters
Identification of a prognostic model using immune related genes combined with tumour mutational burden and T cell infiltration in triple-negative breast cancer.
- 1 Jun 2026
- Oncology letters
Exploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments.
- 1 Jun 2026
- Oncology letters
Clinical predictors of leptomeningeal metastasis from lung adenocarcinoma based on retrospective analysis.
- 1 Jun 2026
- Oncology letters
Advances in cerebrospinal fluid biomarkers for the diagnosis, treatment and monitoring of leptomeningeal metastases (Review).
- 1 Jun 2026
- Oncology letters
Expression of Concern] In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism.
- 1 Jul 2026
- Oncology letters
Expression of Concern] Long non-coding RNA BX357664 inhibits cell proliferation and metastasis in human lung cancer.
- 1 Jun 2026
- Oncology letters
Identification of a prognostic model using immune related genes combined with tumour mutational burden and T cell infiltration in triple-negative breast cancer.
- 1 Jun 2026
- Oncology letters
Exploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments.
- 1 Jun 2026
- Oncology letters
Clinical predictors of leptomeningeal metastasis from lung adenocarcinoma based on retrospective analysis.
- 1 Jun 2026
- Oncology letters
Advances in cerebrospinal fluid biomarkers for the diagnosis, treatment and monitoring of leptomeningeal metastases (Review).
- 1 Jun 2026
- Oncology letters
FAQs on Oncology Letters
How long has Oncology Letters been actively publishing? 
What is the publishing frequency of Oncology Letters?
How many articles did Oncology Letters publish last year?
What is the eISSN & pISSN for Oncology Letters?
What is Citescore for Oncology Letters?
What is SNIP score for Oncology Letters?
What is the SJR for Oncology Letters?
Who is the publisher of Oncology Letters?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations